Want to see IN:SUPRIYA full AI Analyst Report?
Top Page
Supriya Lifescience Limited
(SUPRIYA)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹966.00
▲(28.63% Upside)
Action:Downgraded
Date:10/08/26
The score is primarily supported by strong financial performance, especially the conservative balance sheet and solid recent operating results. This is tempered by a mixed near-term technical picture and a relatively high P/E alongside a minimal dividend yield.
Positive Factors
Revenue Growth
Strong multi-year revenue expansion indicates recovering demand and broader commercial traction across the API portfolio. Continued top-line growth can improve manufacturing utilization, support operating leverage, and provide a durable base for reinvestment in products and capacity.
Negative Factors
Free Cash Flow Volatility
The history of negative free cash flow shows that cash generation has not been consistently predictable, potentially reflecting periods of heavy investment or working-capital swings. Although the recent rebound is strong, future expansion may continue to produce uneven internally available cash.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong multi-year revenue expansion indicates recovering demand and broader commercial traction across the API portfolio. Continued top-line growth can improve manufacturing utilization, support operating leverage, and provide a durable base for reinvestment in products and capacity.
Read all positive factors
Supriya Lifescience Limited (SUPRIYA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹69.89B
Dividend Yield0.12%
Average Volume (3M)14.74K
Price to Earnings (P/E)35.3
Beta (1Y)1.37
Revenue Growth28.14%
EPS Growth11.38%
CountryIN
Employees607
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)24.65
Shares Outstanding80,482,800
10 Day Avg. Volume8,338
30 Day Avg. Volume14,740
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)3.78
Price to Sales (P/S)5.46
P/FCF Ratio105.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)29.5
Revenue Forecast (FY)₹9.94B
Supriya Lifescience Limited Business Overview & Revenue Model
Company Description
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic,...
How the Company Makes Money
Supriya Lifescience primarily makes money by manufacturing and selling active pharmaceutical ingredients (APIs) to customers that formulate and market finished pharmaceutical products. Revenue is earned from (1) API sales across its product portfo...
Supriya Lifescience Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.75B | 8.28B | 6.96B | 5.57B | 4.51B | 5.19B |
| Gross Profit | 5.63B | 4.49B | 3.84B | 2.80B | 2.20B | 2.89B |
| EBITDA | 3.01B | 3.05B | 2.71B | 1.84B | 1.37B | 2.22B |
| Net Income | 1.98B | 2.09B | 1.88B | 1.19B | 898.57M | 1.52B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 13.57B | 11.12B | 9.21B | 8.20B | 7.35B |
| Cash, Cash Equivalents and Short-Term Investments | 788.67M | 788.67M | 791.54M | 749.56M | 1.58B | 2.25B |
| Total Debt | 0.00 | 54.35M | 53.80M | 54.88M | 224.68M | 274.15M |
| Total Liabilities | -11.98B | 1.59B | 1.16B | 1.06B | 1.21B | 1.19B |
| Stockholders Equity | 11.98B | 11.98B | 9.97B | 8.15B | 6.99B | 6.16B |
Cash Flow | ||||||
| Free Cash Flow | 133.16M | 429.88M | 101.89M | -323.48M | -422.13M | -111.03M |
| Operating Cash Flow | 555.65M | 1.95B | 1.73B | 1.13B | 661.87M | 488.01M |
| Investing Cash Flow | -304.29M | -1.88B | -1.52B | -1.74B | -1.24B | -598.22M |
| Financing Cash Flow | -10.75M | -79.93M | -82.33M | -223.59M | -102.76M | 1.50B |
Supriya Lifescience Limited Technical Analysis
Positive
751.00
Price Trends
873.73
Negative
883.14
Negative
784.43
Positive
Market Momentum
-13.10
Positive
48.58
Neutral
57.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUPRIYA, the sentiment is Positive. The current price of 751 is below the 20-day moving average (MA) of 873.42, below the 50-day MA of 873.73, and below the 200-day MA of 784.43, indicating a neutral trend. The MACD of -13.10 indicates Positive momentum. The RSI at 48.58 is Neutral, neither overbought nor oversold. The STOCH value of 57.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SUPRIYA.
Supriya Lifescience Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₹69.89B | 35.27 | ― | 0.12% | 28.14% | 11.38% | |
63 Neutral | ₹95.37B | 37.16 | ― | 0.24% | -27.51% | -34.49% | |
56 Neutral | ₹23.37B | 34.35 | ― | 0.11% | -20.86% | -34.51% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹40.15B | -39.46 | ― | 0.08% | 68.95% | -55.82% | |
50 Neutral | ₹180.00B | -10,464.00 | ― | ― | 10.66% | -104.59% | |
47 Neutral | ₹19.98B | -280.95 | ― | 0.56% | 10.26% | -162.02% |
* General Sector Average
IN:SUPRIYA
Supriya Lifescience Limited
868.40
93.72
12.10%
IN:BLUEJET
Blue Jet Healthcare Limited
503.85
-151.08
-23.07%
IN:DCAL
Dishman Carbogen Amcis Ltd.
149.05
-142.70
-48.91%
IN:PANACEABIO
Panacea Biotec Limited
326.15
-111.60
-25.49%
IN:ZOTA
Zota Health Care Ltd.
1,323.60
-186.08
-12.33%
IN:ONESOURCE
OneSource Specialty Pharma Limited
1,569.65
-286.90
-15.45%
Supriya Lifescience Limited Corporate Events
Supriya Lifescience Schedules Virtual Investor Meet, Posts Presentation Online
Sep 20, 2026
Supriya Lifescience Limited has announced that its officials will hold a virtual group meeting with analysts and institutional investors on Friday, September 25, 2026, from 11:00 a.m. to 12:00 noon. The company has also made its latest investor pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.